Not all KU technology is as big a commercial success as Abilify®, but it’s a great example of how innovation, research and protecting intellectual property are helping society and funding further research at KU.
Immunogenetix Therapeutics, Inc. is an early stage biotechnology company developing advanced DNA-based therapies for the prevention and treatment of HIV infection. DNA-based therapies offer significant advantages over recombinant protein therapies, including an enhanced cellular immune response and long-term protection against viral diseases that require cellular immunity (e.g. HIV). The Company has exclusive worldwide rights to proprietary therapeutic candidates and supporting technologies.